Healthcare provider profile · identity verified

Jonathan Juturu Jack, MD

Allopathic & Osteopathic Physicians|Internal Medicine · ROANOKE RAPIDS, NC · NPI 1730250267

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jonathan Juturu Jack, MD received $111.37 in general payments during 2025 across 5 reported records.

Amgen Inc. accounted for 28.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 6 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$111.37

5 reported records · 5 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Amgen Inc.	Unresolved — no canonical attribution shown	$31.76	28.5%	1	2025
Medtronic, Inc.	Medtronic, Inc. exact · evidence 2025-07-22	$23.17	20.8%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$21.49	19.3%	1	2025
Bayer Healthcare Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$18.68	16.8%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$16.27	14.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$111.37	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REPATHA Normalized: repatha	Biological	Amgen Inc.	$31.76	1	2025
Source payment records 2025-02-13 · Amgen Inc. · $31.76 · Open Payments source
INCEPTIV Normalized: inceptiv	Device	Medtronic, Inc.	$23.17	1	2025
Source payment records 2025-07-31 · Medtronic, Inc. · $23.17 · Open Payments source
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$21.49	1	2025
Source payment records 2025-05-09 · GlaxoSmithKline, LLC. · $21.49 · Open Payments source
Kerendia Normalized: kerendia	Drug	Bayer Healthcare Pharmaceuticals Inc.	$18.68	1	2025
Source payment records 2025-07-29 · Bayer Healthcare Pharmaceuticals Inc. · $18.68 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$16.27	1	2025
Source payment records 2025-08-19 · Lilly USA, LLC · $16.27 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$16.27	1	2025
Source payment records 2025-08-19 · Lilly USA, LLC · $16.27 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	22 Beneficiary count suppressed	exact normalized	Medicare Part D
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	39 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	AREXVY open payments reported associated product	CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445	Arexvy · 2024 Exact normalized brand match · 1 Part D row	34	34
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	SHINGRIX open payments reported associated product	CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452	Shingrix · 2024 Exact normalized brand match · 1 Part D row	32	22
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	39	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	794	180
Amlodipine Besylate	Amlodipine Besylate	759	186
Omeprazole	Omeprazole	513	116
Rosuvastatin Calcium	Rosuvastatin Calcium	414	116
Metoprolol Succinate	Metoprolol Succinate	394	95
Levothyroxine Sodium	Levothyroxine Sodium	392	92
Losartan Potassium	Losartan Potassium	386	84
Furosemide	Furosemide	366	94
Fluticasone Propionate	Fluticasone Propionate	316	133
Gabapentin	Gabapentin	302	74
Pantoprazole Sodium	Pantoprazole Sodium	297	75
Lisinopril	Lisinopril	291	81
Simvastatin	Simvastatin	268	56
Metoprolol Tartrate	Metoprolol Tartrate	265	66
Tramadol Hcl	Tramadol Hcl	254	49
Metformin Hcl	Metformin Hcl	248	59
Eliquis	Apixaban	236	46
Lorazepam	Lorazepam	227	40
Glimepiride	Glimepiride	222	46
Pravastatin Sodium	Pravastatin Sodium	220	53
Sertraline Hcl	Sertraline Hcl	213	48
Tamsulosin Hcl	Tamsulosin Hcl	210	54
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	196	45
Montelukast Sodium	Montelukast Sodium	196	48
Potassium Chloride	Potassium Chloride	191	38
Albuterol Sulfate Hfa	Albuterol Sulfate	184	63
Duloxetine Hcl	Duloxetine Hcl	182	28
Carvedilol	Carvedilol	172	37
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	163	43
Ropinirole Hcl	Ropinirole Hcl	151	40
Allopurinol	Allopurinol	147	36
Clopidogrel	Clopidogrel Bisulfate	142	39
Cephalexin	Cephalexin	138	100
Hydrochlorothiazide	Hydrochlorothiazide	118	38
Famotidine	Famotidine	117	29
Clonazepam	Clonazepam	115	16
Ezetimibe	Ezetimibe	110	27
Celecoxib	Celecoxib	107	41
Quetiapine Fumarate	Quetiapine Fumarate	107	22
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	102	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	99	18
Xarelto	Rivaroxaban	97	35
Doxepin Hcl	Doxepin Hcl	93	27
Spironolactone	Spironolactone	93	25
Prednisone	Prednisone	88	23
Oxycodone Hcl	Oxycodone Hcl	82	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	80	14
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	79	32
Trazodone Hcl	Trazodone Hcl	79	18
Metformin Hcl Er	Metformin Hcl	77	17
Pioglitazone Hcl	Pioglitazone Hcl	77	15
Mirtazapine	Mirtazapine	76	15
Atenolol	Atenolol	72	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	72	51
Hydralazine Hcl	Hydralazine Hcl	71	16
Ozempic	Semaglutide	66	14
Pregabalin	Pregabalin	63	11
Donepezil Hcl	Donepezil Hcl	62	suppressed
Levetiracetam	Levetiracetam	61	14
Alendronate Sodium	Alendronate Sodium	60	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	60	29
Alprazolam	Alprazolam	58	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	58	13
Ramipril	Ramipril	57	12
Zolpidem Tartrate	Zolpidem Tartrate	57	13
Esomeprazole Magnesium	Esomeprazole Magnesium	54	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	12
Tresiba Flextouch U-100	Insulin Degludec	51	14
Ventolin Hfa	Albuterol Sulfate	49	13
Buspirone Hcl	Buspirone Hcl	48	suppressed
Citalopram Hbr	Citalopram Hydrobromide	47	12
Torsemide	Torsemide	47	19
Benazepril Hcl	Benazepril Hcl	46	14
Diclofenac Sodium	Diclofenac Sodium	46	17
Methylprednisolone	Methylprednisolone	43	39
Temazepam	Temazepam	42	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	40	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	40	40
Doxycycline Hyclate	Doxycycline Hyclate	39	27
Memantine Hcl	Memantine Hcl	39	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	39	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	38	19
Finasteride	Finasteride	37	12
Farxiga	Dapagliflozin Propanediol	36	suppressed
Megestrol Acetate	Megestrol Acetate	35	14
Arexvy	Rsvpref3 Antigen/As01e/Pf	34	34
Azithromycin	Azithromycin	34	30
Bupropion Xl	Bupropion Hcl	34	suppressed
Novolog Flexpen	Insulin Aspart	34	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Fenofibrate	Fenofibrate,micronized	32	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	32	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	32	22
Telmisartan	Telmisartan	32	suppressed
Lansoprazole	Lansoprazole	31	suppressed
Tradjenta	Linagliptin	31	suppressed
Digoxin	Digoxin	30	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	suppressed
Meloxicam	Meloxicam	30	suppressed
Primidone	Primidone	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Symbicort	Budesonide/Formoterol Fumarate	29	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	28	28
Fluconazole	Fluconazole	28	20
Fenofibrate	Fenofibrate	27	suppressed
Olanzapine	Olanzapine	27	suppressed
Sucralfate	Sucralfate	27	suppressed
Entresto	Sacubitril/Valsartan	26	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	26	suppressed
Amiodarone Hcl	Amiodarone Hcl	25	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	25	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	25	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	suppressed
Methimazole	Methimazole	24	suppressed
Nystatin	Nystatin	24	suppressed
Terazosin Hcl	Terazosin Hcl	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	22	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	22	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	suppressed
Spiriva Handihaler	Tiotropium Bromide	22	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	22	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Levofloxacin	Levofloxacin	21	17
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Valsartan	Valsartan	20	suppressed
Baclofen	Baclofen	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	18	suppressed
Bumetanide	Bumetanide	18	suppressed
Mupirocin	Mupirocin	18	11
Nitroglycerin	Nitroglycerin	18	12
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	17	suppressed
Cilostazol	Cilostazol	17	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Ammonium Lactate	Ammonium Lactate	16	suppressed
Nateglinide	Nateglinide	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Insulin Aspart Flexpen	Insulin Aspart	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Sotalol	Sotalol Hcl	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Diazepam	Diazepam	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Linzess	Linaclotide	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Ondansetron Odt	Ondansetron	14	13
Veo Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Colesevelam Hcl	Colesevelam Hcl	13	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Mresvia	Rsv Vaccine, Pref, Mrna/Pf	13	13
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Azathioprine	Azathioprine	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Icosapent Ethyl	Icosapent Ethyl	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Trinatal Rx 1	Prenatal Vit27,calcium/Iron/Fa	12	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Estradiol	Estradiol	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Jentadueto	Linagliptin/Metformin Hcl	11	suppressed
Lumigan	Bimatoprost	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Tacrolimus	Tacrolimus	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Victoza 3-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$111.37 · 5 records	Amgen Inc.	INCEPTIV, Kerendia, MOUNJARO, REPATHA, TRELEGY ELLIPTA, ZEPBOUND	6	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error